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Abstract  56 
Background:  57 
Childhood cancer survivors are at increased risk for pulmonary morbidity and mortality. 58 
International guidelines recommend pulmonary function tests (PFT) during follow-up 59 
care. This nationwide study assessed how many children received PFT within five years 60 
after pulmotoxic treatment in Switzerland, types of tests, and predictors for testing. 61 
Methods: 62 
We included all children from the Swiss Childhood Cancer Registry who were 63 
diagnosed with cancer from 1990-2013 at age 0-16 years, survived for ≥2 years from 64 
diagnosis and had pulmotoxic chemotherapy with bleomycin, busulfan, nitrosoureas 65 
and/or chest radiotherapy. We searched medical records in all Swiss pediatric oncology 66 
clinics for PFT (spirometry, plethysmography, diffusion capacity of carbon monoxide 67 
[DLCO]) and treatment details. 68 
Results: 69 
We found medical records for 372 children, of whom 147 had pulmotoxic chemotherapy 70 
and 323 chest radiotherapy. Only 185 had plethysmography and/or spirometry (50%), 71 
122 had DLCO (33%). Testing varied by cancer center from 3% to 79% (p=0.001). 72 
Central nervous system tumor survivors and those not treated according to study 73 
protocols had less plethysmography and/or spirometry (odds ratio (OR): 0.3 and 0.3), 74 
lymphoma survivors and those who were symptomatic had more PFTs 75 
(plethysmography and/or spirometry: OR: 5.9 and 8.7; DLCO: OR: 3.4 and 2.3). 76 
Cumulative incidence of PFT (CuI) was 52% in the first five years after pulmotoxic 77 
treatment; most of the tests were done in the first two years after treatment (CuI 44%). 78 
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Conclusion: 79 
Only half of survivors exposed to pulmotoxic treatment have been followed up with PFT 80 
in Switzerland. We need to optimize, update, and implement monitoring guidelines. 81 
  82 
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Introduction 83 
Every fifth childhood cancer survivor (CCS) is exposed to pulmotoxic cancer 84 
treatment with either bleomycin, busulfan, nitrosoureas and/or radiotherapy involving 85 
lung tissue.1 These treatments can lead to lung damage and pulmonary diseases that 86 
are a major cause of mortality and morbidity in CCS. CCS have a three-fold increased 87 
risk of hospitalization due to pulmonary diseases and up to 14 times increased risk of 88 
late pulmonary death.2-4 In Switzerland, 12% of CCS report one or more pulmonary 89 
diseases, possibly caused by cancer treatment.1 In the St. Jude Lifetime Cohort, in 90 
which all CCS received risk-based screening at a median of 25 years after cancer 91 
treatment, 65% of 417 CCS exposed to pulmotoxic treatment had abnormal pulmonary 92 
function tests (PFT).5 Prior to testing, more than half were unaware of their pulmonary 93 
dysfunction, which was the most frequently detected adverse health effect.5 A similar 94 
study performed in 370 CCS from the City of Hope Hospital also found that the yield of 95 
screening for pulmonary dysfunction was higher (84%) than for other late effects 96 
including hearing loss (23%), low bone mineral density (23%) or hypothyroidism (11%).6 97 
Early detection of pulmonary dysfunction can help guide treatment and inform 98 
lifestyle modifications to mitigate progression and reduce exacerbation.7 Since 1995 99 
international follow-up care guidelines in the UK and since 2003 in the US have 100 
therefore recommended PFT for CCS at risk of pulmonary dysfunction.8,9 Switzerland 101 
has no national guidelines, and routine practice of PFT in follow-up care after childhood 102 
cancer is unknown. 103 
In this national, population-based study we retrospectively studied three aspects 104 
of pulmonary function testing during follow-up care of CCS in Switzerland: the type of 105 
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PFT performed, how many CCS were tested, and the characteristics of CCS who had 106 
had PFT compared to those who had not.  107 
 108 
Methods 109 
Study population 110 
This study is a nested cohort in the Swiss Childhood Cancer Registry (SCCR). 111 
The SCCR includes all children and adolescents who live in Switzerland and are 112 
diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors, malignant 113 
solid tumors, or Langerhans cell histiocytosis prior to the age of 21 years.10 The SCCR 114 
is a national, population-based registry that includes more than 95% of childhood 115 
cancer patients diagnosed since 1995.11 It registers information on cancer diagnosis 116 
and treatment, and personal information. Tumors are classified according to the 117 
International Classification of Childhood Cancer, third edition (ICCC-3).12 Ethics 118 
approval was granted by the Ethics Committee of the Canton of Bern to the SCCR 119 
(KEK-BE: 166/2014). 120 
 121 
Inclusion criteria 122 
We included all CCS registered in the SCCR who were treated with pulmotoxic 123 
chemotherapy and/or chest radiotherapy in a Swiss pediatric oncology center up to the 124 
age of 16 years and aged ≥6 years at time of the study (Supplementary Fig. S1). We 125 
defined pulmotoxic chemotherapy as treatment with busulfan, bleomycin, and/or 126 
nitrosoureas (lomustine, carmustine) according to international follow-up care guidelines 127 
(Supplementary Table S1).8,9 Radiotherapy relevant for this study was defined as any 128 
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radiation applied to the whole body, mantle-field, chest, lungs, mediastinum or thoracic 129 
spine.8,9 We included CCS diagnosed from 1990 to 2013. According to Swiss law, 130 
medical records need to be stored for only 10-20 years so we excluded those CCS 131 
diagnosed before 1990 to preserve completeness of data.13 We excluded CCS 132 
diagnosed after 2013 because treatment was not always completed when data 133 
collection started in 2016.  134 
 135 
Medical records review 136 
For this retrospective data collection, we accessed medical records in 2016 in all 137 
Swiss pediatric oncology centers and the corresponding pediatric respiratory clinics. We 138 
collected PFT, reports of pediatric pulmonologists, reports of ambulatory oncology care, 139 
hospitalization discharge reports, and cancer treatment protocols. 140 
Switzerland has no national recommendations on type and timing of PFT in CCS 141 
after pulmotoxic treatment. We therefore decided on a simplified approach and collected 142 
all PFT performed in the first five years after pulmotoxic treatment regardless of the 143 
reasons for performing the tests. We collected information on all tests specifically 144 
recommended for assessment of pulmonary late effects by international guidelines, i.e. 145 
spirometry, plethysmography and diffusion capacity of carbon monoxide (DLCO),8,9 and 146 
also noted other tests performed including bronchodilator tests, cardiopulmonary 147 
exercise tests, measurement of exhaled nitric oxide, bronchial challenge test, and 148 
multiple breath inert gas washout. We reviewed medical reports from pulmonologists 149 
and pediatric oncology for pulmonary diagnoses, distinguishing between noninfectious 150 
pulmonary diseases and pulmonary infections. Noninfectious pulmonary diseases found 151 
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in the medical records were asthma, diffuse parenchymal lung disease (restrictive lung 152 
disease, interstitial lung disease, bronchiolitis obliterans), atelectasis, chest wall 153 
deformity, emphysema, and acute respiratory distress syndrome (ARDS). Infections 154 
listed in the records were viral or bacterial pneumonia and aspergillosis. CCS who had 155 
both noninfectious pulmonary disease and infection, were classified as having 156 
noninfectious pulmonary disease, which we considered more permanent. 157 
We collected detailed information on cancer treatment from the SCCR or, when it 158 
was not available in the SCCR, medical records, recording the start date of pulmotoxic 159 
treatment. We classified CCS into three groups depending on the pulmotoxic treatment: 160 
chest radiotherapy, pulmotoxic chemotherapy, or both. We determined whether CCS 161 
were registered clinical study participants, were treated according to a clinical study 162 
protocol but not registered, or were not treated according to a clinical study protocol. If 163 
children received multiple pulmotoxic treatments (e.g. for primary tumor and relapse) 164 
the last treatment was the one used in categorization of clinical study participation. We 165 
recorded information on thoracic surgery with thoracotomy or thoracoscopy for 166 
tumor/metastasis resection (wedge, lobe, whole lung), rib resection, laminectomy, bone 167 
biopsy, en bloc resection of rib, lung tissue, and/or diaphragm. We recorded autologous 168 
or allogeneic hematopoietic stem cell transplantation (HSCT). We also collected 169 
information on relapse of the cancer and survival. 170 
 171 
Statistical analysis 172 
We assessed the proportion of CCS who had different types of PFT during the 173 
first 5 years after pulmotoxic treatment. Among those who had been tested, we 174 
 11 
 
calculated the median number, interquartile range, and range of PFT. We stratified the 175 
results by sex, age at diagnosis, diagnosis, period of cancer diagnosis, pulmotoxic 176 
treatment, thoracic surgery, HSCT, clinical study participation, pulmonary disease 177 
diagnosis, or death during follow-up care and assessed associations using univariable 178 
and multivariable logistic regression models. In a sensitivity analysis we excluded all 179 
children with asthma (19 children) from the model, because we suspected that children 180 
with asthma would receive PFT to assess asthma control rather than screen for 181 
sequelae of cancer treatment. Finally, we used the Kaplan-Meier method to estimate 182 
cumulative incidence curves for PFT performed during the first five years after 183 
pulmotoxic treatment overall, and stratified by period of cancer diagnosis. CCS who had 184 
not had a PFT were censored at five years of follow-up, death, or start of data collection 185 
(February 2, 2016), whichever occurred first. In eight cases in which we had no 186 
information on the start of pulmotoxic treatment, we considered the start date to be the 187 
date of the cancer diagnosis. 188 
We used Stata (Version 14, Stata Corporation, Austin, Texas) for all analyses. 189 
 190 
Results 191 
Characteristics of study population 192 
Of 2989 eligible CCS, 419 (14%) received pulmotoxic treatment and were at 193 
least six years old at start of data collection. Medical records were unavailable in 47 of 194 
those CCS (Supplementary Fig. S1). Table 1 lists the characteristics of the 372 CCS 195 
included in the analysis, 147 of whom had received pulmotoxic chemotherapy (40%), 196 
while 324 received chest radiotherapy (87%). Pulmonary diseases were present in 72 197 
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CCS, of whom 47 had noninfectious pulmonary disease and 25 pulmonary infections 198 
(Supplementary Table S2). 199 
 200 
Pulmonary function tests  201 
Within five years after pulmotoxic treatment, 185 of 372 CCS (50%) had received 202 
at least one PFT. All 185 CCS in whom pulmonary function had been tested had at least 203 
a spirometry and/or body plethysmography; the median number of plethysmography 204 
and/or spirometry tests per tested child was 3 (IQR 2–5). DLCO was done at least once 205 
in 122 CCS (33%), and the median number of DLCO per tested child was 3 (IQR 2–4). 206 
Other tests performed were bronchodilator tests, cardiopulmonary exercise tests, 207 
fractionated exhaled nitric oxide, bronchial challenge tests, and multiple breath inert gas 208 
washout (Table 2). 209 
 210 
Predictors for pulmonary function tests 211 
Testing varied strongly by cancer treatment centers: center A was clearly above 212 
average and had done both plethysmography and/or spirometry and DLCO in 79% of 213 
children. All other centers did plethysmography and/or spirometry in 26% to 58%, and 214 
DLCO in 3% to 44% (Fig. 1, Supplementary Table S3). Children who were older at 215 
diagnosis were more often tested (had higher odds for being tested) than those younger 216 
at diagnosis, although age at diagnosis was not statistically significant after adjustment 217 
(Table 3, Supplementary Table S4). Compared to patients with leukemia, survivors of 218 
lymphoma were tested more often (odds ratio (OR) 5.9 for plethysmography and 219 
spirometry, OR 3.4 for DLCO). CNS tumor survivors were tested less often with 220 
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plethysmography and spirometry (OR 0.3), and we observed a tendency for less DLCO 221 
measurements, although statistically not significant (OR 0.5). Pulmonary function was 222 
tested equally often in children registered as a clinical study participant and those 223 
treated according to a study protocol, but those not treated according to a study protocol 224 
had less often plethysmographies and/or spirometries (OR 0.3). CCS diagnosed with a 225 
noninfectious pulmonary disease were tested much more often than those without 226 
pulmonary diseases or pulmonary infections (plethysmography and spirometry OR 8.7, 227 
DLCO OR 2.3).  228 
We observed no differences by gender, period of cancer diagnosis, pulmotoxic 229 
treatments, thoracic surgery and HSCT (Table 3). In a sensitivity analysis in which we 230 
excluded all patients with asthma, results were essentially the same.  231 
 232 
Cumulative incidence of pulmonary function tests 233 
The cumulative incidence of children who had a PFT was 31% one year after 234 
pulmotoxic treatment, 44% after two years, 48% after three years, 51% after four years, 235 
and 52% after five years. Cumulative incidence did not differ between periods of cancer 236 
diagnosis (Fig. 2).  237 
Discussion 238 
In our nationwide study of all children who were diagnosed with cancer and 239 
exposed to pulmotoxic treatment in Switzerland between 1990 and 2013, we found that 240 
only half had PFT during follow-up care. This contrasts sharply with international 241 
recommendations (Supplementary Table S1).8,9 Only 50% of children had a 242 
plethysmography and/or spirometry, and only 33% a DLCO. This did not depend on 243 
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type of pulmotoxic treatment, but varied significantly between treatment centers and 244 
test, from 3% to 79%. Lymphoma survivors and those diagnosed with a non-infectious 245 
pulmonary disease were most likely to be tested, while CNS tumor survivors and those 246 
not treated according to a study protocol were least likely tested. Most children had the 247 
first test within 2 years after pulmotoxic treatment. 248 
Guidelines for PFT in follow-up care differ for type of test and timing. US follow-249 
up care guidelines recommend performing a PFT at entry into long-term follow-up which 250 
is defined as “two or more years after completion of therapy” in children exposed to 251 
pulmotoxic chemotherapy and/or chest radiotherapy, and thereafter as clinically 252 
indicated.9 They recommend performing a spirometry and a DLCO. UK follow-up care 253 
guidelines recommend PFT in exposed children at the end of treatment without further 254 
specifying the type of test. In children with symptoms or an abnormal first PFT, the test 255 
should be repeated after one year.8  256 
In single centers like St. Jude Children’s Research Hospital and City of Hope in 257 
the US, follow-up care guidelines are implemented among CCS enrolled in life-time 258 
cohorts or long term follow-up clinics.5,6 For the St. Jude life-time cohort 2843 (60%) of 259 
survivors participated in long-term follow-up. Among those, all ten-year survivors with 260 
pulmotoxic exposure (n=417, 100%) were screened according to their follow-up 261 
guidelines.5 However, no previous study has investigated PFT in follow-up care on a 262 
national level, and in our study we found that only 50% of the children had had PFT. We 263 
have reports from single centers in Europe as well, where pulmonary function outcomes 264 
in CCS have been studied retrospectively. In a Dutch study, 193 of 220 (88%) CCS 265 
exposed to pulmotoxic treatment had a PFT. This is more than in Switzerland, but less 266 
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than optimal, considering that the center observes follow-up care guidelines from the 267 
US.14 In an Israeli study of 170 survivors of HSCT, only 34% had had PFT according to 268 
their hospital internal protocol.15 This study cannot be compared directly to ours as the 269 
Israeli protocol was stricter and required more tests, including PFT before HSCT, and at 270 
3, 6, and 12 months post-HSCT. No study has investigated in detail which PFT were 271 
done in children exposed to pulmotoxic treatments. In our study, DLCO was measured 272 
in only 33% of children, which is surprising, since it is a sensitive measure for detecting 273 
mild or preclinical interstitial lung disease and helps distinguish interstitial lung disease 274 
from extra-pulmonary causes of restriction.16 Moreover, it is noninvasive, cheap, and 275 
needs little time. Also, multiple breath inert gas washout, which measures lung 276 
clearance index, was rarely used, although it is sensitive for detection of early small 277 
airway disease. Four of the eight pediatric cancer treatment centers had the setup to 278 
perform such measurements by 2016 and obviously did not use it for screening of CCS, 279 
but mainly for patients with other lung diseases such as cystic fibrosis and for research 280 
rather than clinical purposes.17,18 281 
The most important predictor for pulmonary function testing was the treatment 282 
center, with proportions varying from 24% to 79% for plethysmography and/or 283 
spirometry and 3% to 44% for DLCO. This did not depend on the size of the center. We 284 
observed the highest proportion in a smaller center with only 28 exposed CCS. This 285 
center always performed DLCO together with plethysmography and/or spirometry in 286 
CCS. All other centers tested DLCO only in some of the children who had spirometry 287 
and/or plethysmography; in three centers the frequency was very low (≤6%). This 288 
indicates that centers have different practices of follow-up care or possibly do not follow 289 
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any guidelines and, in general have different algorithms for performing PFT. Children 290 
diagnosed with a noninfectious pulmonary disease had more PFT than those without. 291 
PFT might not have been planned as part of follow-up care but may have been 292 
prescribed in response to symptoms. Children with pneumonia or aspergillosis did not 293 
have more PFT. This reflects clinical management in which pulmonary infections are not 294 
investigated primarily with pulmonary function tests, but rather blood sampling and 295 
imaging. CNS tumor survivors were tested the least often. Most CNS tumor survivors, 296 
95 of 107 (89%), received craniospinal radiotherapy, 63 (59%) received nitrosoureas 297 
(Supplementary Table S5). The existing follow-up care guidelines all recommend follow-298 
up care for nitrosoureas, but disagree on craniospinal radiotherapy: UK guidelines 299 
recommend PFT, while US guidelines do not.8,9 When we excluded CCS with 300 
craniospinal irradiation from the regression and found that CNS tumor survivors still had 301 
less pulmonary function tests compared to leukemia survivors. An explanation might be 302 
that survivors of CNS tumors often have multiple morbidities, which can shift the 303 
attention of clinicians away from the lung.19 Clinicians might have skipped PFT because 304 
they thought that other tests might be more important, or the children were regarded as 305 
unable to perform PFT.  306 
Children treated for lymphomas were tested most often. Lymphomas have the 307 
best survival rates among all childhood cancers.20 Late effects after lymphoma are well 308 
studied and physicians’ awareness for pulmonary late effects is clearly highest.21,22 This 309 
might also have been influenced by the historically more extensive radiation fields 310 
involving parts of the lungs  g to a study protocol had less PFT. Children cannot be 311 
treated according to a protocol when there is no study protocol for their specific disease, 312 
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or they fail to meet inclusion criteria of existing protocols. Although this situation can 313 
complicate cancer treatment during the acute phase, it should not stop physicians’ from 314 
doing PFT during follow-up visits. CCS who were treated according to a study protocol 315 
had the same likelihood of receiving PFT as those children registered as study 316 
participants. Some study protocols containing pulmotoxic treatment have follow-up care 317 
recommendations for PFT, and physicians seem to follow such recommendations 318 
regardless of whether children are registered participants about half time. However, not 319 
all study protocols recommend PFT after pulmotoxic therapy; the HIT-2000 protocol, for 320 
example does not do so (Supplementary Table S1). In our study, the proportion of 321 
children tested did not depend on the type of pulmotoxic treatment the children had 322 
received. Even CCS with a combination of pulmotoxic chemotherapy and radiotherapy 323 
were not tested more often. The two international guidelines that are best known to 324 
Swiss oncologists were published after 1995 (UK 1995, US 2003).8,9 Yet, our data do 325 
not suggest these guidelines have been implemented in Swiss clinics, since the 326 
numbers of tests did not increase after publication of the respective guidelines.  327 
The study was a retrospective chart review in the Swiss pediatric oncology centers. If 328 
PFT was done in private practice or other clinics without reporting results, our search 329 
would have missed them. But this scenario is unlikely as nearly all CCS are seen in 330 
follow-up by their cancer center during the first five years. Spirometry, plethysmography, 331 
and DLCO are available in all centers and would have been done there. We did not 332 
investigate whether a first PFT was performed later than five years after diagnosis as 333 
long term follow up guidelines recommend the initiation either at the end of cancer 334 
treatment (UK),8 or two or more years after completion of therapy (US).9 However, our 335 
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study is likely to have overestimated the adherence to guidelines because we had no 336 
detailed information on the indication for PFT. We hypothesized that pulmonary function 337 
tests are done often because survivors have symptoms or already diagnosed 338 
pulmonary disease rather than because physicians follow international monitoring 339 
recommendations on risk based screening. We used presence of pulmonary disease as 340 
surrogate for symptoms or diagnosed pulmonary disease before testing. Our analysis 341 
supported our initial hypothesis and found that having a symptomatic pulmonary 342 
disease is the strongest predictor for having PFTs during follow-up care.  343 
 Some guidelines and study protocols recommend imaging such as chest x-ray or 344 
computer tomography, but we did not collect this information, because in some clinics 345 
access to radiology departments was difficult. Finally, for some participants 346 
chemotherapy doses could not be found because in certain older records not all 347 
treatment information was available. In such cases we could only confirm whether CCS 348 
had chemotherapy.  349 
The strengths of our study include the nationwide, population-based setting. We 350 
had original information from medical records to investigate lung health monitoring; we 351 
were able to include CCS with different childhood cancer diagnoses and different 352 
treatment protocols. Having exact dates of pulmotoxic treatment and PFT made it 353 
possible to analyze the timing of monitoring in detail. We also considered children 354 
diagnosed over an extended period (1990-2013), which allowed us to evaluate potential 355 
changes over the last 23 years. 356 
Surveillance of pulmonary disease is insufficient in Switzerland, particularly for 357 
CNS tumor survivors and those not treated according to study protocols in particular are 358 
 19 
 
monitored very rarely. The lack of national monitoring guidelines might have contributed 359 
to insufficient surveillance of pulmonary health. The proportions of PFT performed in 360 
Swiss centers also vary widely across the centers. Physicians should therefore be 361 
surveyed to explore which monitoring guidelines they know and follow, the reasons why 362 
they schedule PFT, and why CNS tumor survivors are neglected. Clinicians’ knowledge 363 
of the importance of pulmonary monitoring after cancer treatment needs to improve. 364 
We observed further that existing guidelines are inconsistent.8,9 Physician 365 
compliance might improve were guidelines harmonized. The need for standardized 366 
guidelines for follow-up care was recognized by oncologists and general practitioners in 367 
adult and pediatric care in a recent study among Swiss physicians.23 The International 368 
Late Effects of Childhood Cancer Guideline Harmonization Group (www.ighg.org) is 369 
currently developing recommendations for pulmonary disease surveillance after cancer 370 
treatment to harmonize existing recommendations.24 The new guidelines, based on 371 
current literature, existing guidelines, and broad expert consensus, will propose 372 
recommendations about who needs monitoring at what frequency, for how long, and the 373 
modalities that should be used (e.g., which PFT, or imaging). Upon publication, these 374 
guidelines should be adapted to local needs of different countries and then implemented 375 
to offer high quality follow-up care to all former cancer patients.  376 
  377 
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Table 1 Characteristics of childhood cancer survivors 
 Survivors 
 N = 372 
 n (%) a 
Sex   
Male 219 (59) 
Female 153 (41) 
   
Age at diagnosis in years   
Median (range) 10.2  (0.3–15.9) 
0–4 67 (18) 
5–9 111 (30) 
10–15 194 (52) 
 
  
Age at data collection in yearsb 
  
Median (range) 23.4  (6.2–40.7) 
6–14 67 (18) 
15–24 152 (41) 
≥ 25 153 (41) 
 
  
Time since cancer diagnosis in years   
Median (range) 13.2 (2.0–25.9) 
2–9 139 (37) 
10–19 156 (42) 
≥ 20 77 (21) 
 
  
Period of cancer diagnosis   
1990–1997 130 (35) 
1998–2005 144 (39) 
2006–2013 98 (26) 
   
Diagnosis (ICCC-3)   
I Leukemia 46 (12) 
II Lymphoma 131 (35) 
IIa Hodgkin's lymphoma 120 (32) 
IIb&c Non–Hodgkin's lymphoma 11 (3) 
III CNS tumor 107 (29) 
IV–XII all other tumors  88 (24) 
   
Relapse   
Yes, one relapse 71 (19) 
Yes, two or more relapses 46 (12) 
   
Death during follow-up c 57 (15) 
   
Lung-toxic chemotherapy 147 (40) 
Busulfan 24 (6) 
Nitrosoureas (CCNU/BCNU) 70 (19) 
Bleomycin 57 (15) 
   
2 
 
Table 1 continued 
Chest radiotherapy, cumulative Gy 323 (87) 
1–19 116 (31) 
≥ 20 197 (53) 
Dose unknown 10 (3) 
   
Thoracic surgery  34 (9) 
   
Hematopoietic stem cell transplantation  87 (24) 
Autologous 47 (13) 
Allogeneic  40 (11) 
   
Clinical study participation   
Registered as clinical study participant 217 (58) 
Treated according to clinical study protocol 124 (34) 
Treated not according to clinical study 31 (8) 
   
 
Abbreviations: CNS, central nervous system; Gy, Gray; ICCC3, International Classification of 
Childhood Cancer, version 3; IQR, interquartile range 
 
a Column percentages are given 
b Time from pulmotoxic treatment to start of study or date of death 
c Death during the whole time observed. 
d Including radiotherapy to the total body, mantle-field, thorax, lungs, mediastinum or thoracic spine. 
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Table 2 Types of pulmonary function test performed in the first five years after 
pulmotoxic treatment 
 Survivors with 
pulmonary 
function test 
 Number of specific 
pulmonary function tests 
in survivors with at least 1 
specific pulmonary 
function test 
(N=372) N (%) a  Median  IQR Range 
 
  
 
   
Tests specifically recommended in  
follow-up care guidelines 
      
Plethysmography and/or spirometry 185  (50)  3 (2–5) (1–11) 
Plethysmography and spirometry 172 (46)  3 (2–5) (1–11) 
Spirometry only 12 (3)  1 (1–1) (1–2) 
Plethysmography only 1 (<1)  1 (1–1) (1–1) 
Diffusion capacity of carbon monoxide 122 (33)  3 (2–4) (1–8)    
 
   
Other tests: 
  
 
   
Bronchodilator test 31 (8)  1 (1–3) (1–6) 
Cardiopulmonary exercise test 11 (3)  1 (1–2) (1–2) 
Exhaled nitric oxide 7 (2)  1 (1–2) (1–5) 
Bronchial challenge test 3 (1)  1 (1–2) (1–2) 
Multiple breath inert gas washout 2 (1)  1.5 (1–2) (1–2) 
       
 
Abbreviations: IQR, interquartile range  
a Row percentages are given 
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Table 3 Predictors for having a pulmonary function test in the first 5 years after pulmotoxic treatment, results from multivariable logistic 
regression analysis 
 
 
Plethysmography and / or 
spirometry 
 DLCO  
 
 
 
≥ 1 PFT  ≥ 1 PFT 
 
    
P b  
   
P b 
 N=37
2 
n (%)a ORadj (95% CI)  n (%)a ORa
dj 
(95% CI) 
Overall  372 185 (50) 
  
 122 (33) 
  
     
  
   
 
Sex 
    
0.543  
   
0.748 
Male 219 105 (48) 1.0   70 (32) 1.0  
Female  70 80 (52) 1.2 (0.7–1.9)  52 (34) 0.9 (0.6–1.5)      
  
   
 
Age at diagnosis (years) 
    
0.591  
   
0.331 
0–4 67 26 (39) 1.0   13 (19) 1.0  
5–9 111 47 (42) 1.5 (0.7–3.2)  30 (27) 1.7 (0.8–3.8) 
10–15 194 112 (58) 1.3 (0.6–2.6)  79 (41) 1.7 (0.8–3.8)      
  
   
 
Diagnosis (ICCC-3) 
    
<0.001  
   
<0.001 
I Leukemia 46 20 (43) 1.0   10 (22) 1.0  
II Lymphoma 131 100 (76) 5.9 (2.2–16.1)  67 (51) 3.4 (1.2–9.5) 
IIa Hodgkin's lymphoma 120 94 (78)    61 (51) 
 
 
IIb&c Non–Hodgkin's lymphoma 11 6 (55)    6  (55) 
 
 
III CNS tumor 107 22 (21) 0.3 (0.1–1.0)  16 (15) 0.5 (0.1–1.5) 
IV–XII all other tumors  88 43 (49) 1.2 (0.5–3.2)  29 (33) 1.8 (0.6–5.0)     
   
   
 
Period of cancer diagnosis 
   
 0.441  
   
0.100 
1990–1997 130 63 (48) 1.0   40 (31) 1.0  
1998–2005 144 77 (53) 1.5 (0.8–2.7)  55 (38) 1.7 (0.9–3.0) 
2006–2013 98 45 (46) 1.2 (0.6–2.4) 
 
27 (28) 1.0 (0.5–2.4) 
2 
 
Table 3 continued 
Pulmotoxic treatment 
    
0.408 
    
0.278 
Chest radiotherapy  225 113 (50) 1.0  
 
72 (32) 1.0  
Pulmotoxic chemotherapy  48 24 (50) 1.6 (0.8–3.4) 
 
14 (29) 1.1 (0.5–2.4) 
Both 99 48 (48) 1.3 (0.7–2.5) 
 
36 (36) 1.7 (0.9–3.0)      
 
    
 
Thoracic surgery  
    
0.237 
    
0.852 
No 338 165 (49) 1.0  
 
110 (33) 1.0  
Yes 34 20 (59) 1.8 (0.7–4.9) 
 
12 (35) 0.9 (0.4–2.3)      
 
   
  
Hematopoietic stem cell transplantation 
    
0.407 
   
 0.861 
No 285 141 (49) 1.0  
 
97 (34) 1.0  
Yes 87 44 (51) 1.4 (0.6–2.9) 
 
25 (29) 0.9 (0.4–2.0) 
autologous 47 24 (51)    15 (32)   
allogeneic 40 20 (50)    10 (25)   
           
Clinical study participation     0.010     0.082 
Registered as clinical study participant 217 113 (52) 1.0   69 (32) 1.0  
Treated according to clinical study protocol 124 65 (52) 1.5 (0.9–2.7)  46 (37) 1.8 (1.0–3.2) 
Treated not according to clinical study 31 7 (23) 0.3 (0.1–0.9)  7 (23) 0.9 (0.3–2.5)      
 
    
 
Ever had a pulmonary disease/infection  
    
<0.001 
    
0.072 
No 300 137 (46) 1.0  
 
92 (31) 1.0  
Noninfectious pulmonary disease 47 38 (81) 8.7 (3.4–22.4) 
 
22 (47) 2.3 (1.1–4.5) 
Pulmonary infection 25 10 (40) 0.7 (0.3–1.9) 
 
8 (32) 1.3 (0.5–3.4)      
 
   
  
Died during follow-up 
    
0.709 
    
0.969 
No 315 165 (52) 1.0  
 
107 (34) 1.0  
Yes  57 20 (35) 0.9 (0.4–1.9)   15 (26) 1.0 (0.5–2.2) 
  
3 
 
Table 3 continued 
Abbreviations: CI, confidence interval; CNS, central nervous system, DLCO, diffusion capacity of the lungs for carbon monoxide; ICCC3, international 
classification of childhood cancer, version 3; OR, odds ratio; PFT, pulmonary function test  
a Row percentages given. 
b P-values calculated from global likelihood ratio tests  
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Supplementary Table S1 Recommendations for surveillance of pulmonary dysfunction in international follow-up care guidelines and 
treatment protocols 
Guidelines 
 
   
 Exposure Recommended evaluation Timing 
Children’s Cancer Study Group (Late 
Effects Group) Long Term Follow-up 
Guidelines 1 
Therapy based long term follow-up: practice 
statement UK, 2nd edition, April 2002 
1st edition 1995 
 
 
Alkylating agents 
- Busulfan 
- Carmustine 
- Lomustine  
Bleomycin  
Chest radiotherapy (including spine) 
Thoracic surgery  
HSCT (with or without cGvHD) 
Pulmonary function test, no 
further specification 
At end of treatment 
and if symptomatic or 
abnormal (<2SD below 
normal), repeat PFT 
after 1 year. 
Children’s Oncology Group–Long-Term 
Follow-Up Guidelines 2 
USA, Version 4.0, October 2013 
1st edition: 2003 
 
 
 
 
 
Alkylating agents 
- Busulfan 
- Carmustine 
- Lomustine 
Bleomycin 
Chest radiotherapy (excluding spine) 
Thoracic surgery  
HSCT with chronic graft versus host 
disease (cGvHD) 
Pulmonary function test 
(including DLCO and 
spirometry) 
Baseline at entry in 
follow-up care, defined 
as two or more years 
after completion of 
therapy. Repeat as 
clinically indicated. 
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(Supplementary Table S1 continued) 
Treatment Protocols 
 
  
 Cancer 
diagnosis 
Na Possible Exposure Recommended evaluation Timing 
GPOH-HD 95 Hodgkin 
Lymphoma 
41 Chest radiotherapy  Pulmonary function tests, no 
further specification 
At the end of treatment 
and then in year 1 and 
2 every 6 months, in 
year 3 and 4 every 
year, year 5 to 10 if 
clinically indicated 
HIT-2000 Medulloblastoma, 
supratentorial 
primitive 
neuroectodermal 
tumor, or 
ependymoma 
34 Craniospinal radiotherapy 
Lomustine 
- - 
SPOG H85/87/92 Hodgkin 
Lymphoma 
30 Chest radiotherapy of the chest 
Bleomycin 
Pulmonary function tests, no 
further specification 
1 year after end of 
therapy if abnormal 
repeat annually, or for 
5 years 
Euro-E.W.I.N.G 99 Ewing Sarcoma 14 Chest radiotherapy  
Busulfan 
Minimum: clinical 
examination 
Pulmonary function tests 
(including DLCO) 
At end of treatment 
and if abnormal repeat 
yearly, if normal repeat 
5 yearly and at the end 
of puberty 
GPOH-HD Pilot 
2002 
Hodgkin 
Lymphoma 
14 Chest radiotherapy 
 
Pulmonary function tests, no 
further specification 
1, 2, and 5 years after 
end of therapy, in 
between if clinically 
indicated 
POG A9961 Average risk 
Medulloblastoma 
10 Craniospinal radiotherapy 
Lomustine 
Pulmonary function tests 
(lung volumes, spirometry 
and DLCO) 
Pretreatment, at end of 
therapy, 1, 3 and 5 
years after the end of 
therapy 
COG ACNS0331 Standard risk 
Medulloblastoma 
8 Craniospinal radiotherapy 
Lomustine 
- - 
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(Supplementary Table S1 continued) 
POG 9031 Advanced 
Medulloblastoma 
8 Craniospinal radiotherapy Late effects evaluation, list of 
available complications 
criteria includes vital 
capacity, DLCO 
- 
EURONet-PHL-C1 
 
Hodgkin 
Lymphoma 
7 Involved field radiotherapy 
Bleomycin (with relapse) 
Carmustine (with relapse) 
Pulmonary function tests, no 
further specification 
6 weeks after end of 
treatment, afterwards 
as clinically indicated 
EWOG-MDS 98 
 
Myelodysplastic 
syndrome  
7 Busulfan - - 
ALL SZT BFM 2003 
 
Acute 
lymphoblastic 
leukemia 
6 Total body irradiation 
Busulfan 
Pulmonary function tests, no 
further specification 
At end of treatment, 
after 6 month, 1, 2 
and 4 years 
HIT 91 
 
Medulloblastoma, 
supratentorial 
primitive 
neuroectodermal 
tumor, or 
ependymoma 
6 Craniospinal radiotherapy 
Lomustine 
- - 
POG 9049 
 
High risk 
malignant germ 
cell tumors 
6 Bleomycin Pulmonary function tests, no 
further specification 
Optimal prior to each 
course of 
chemotherapy, after 
induction and after 
maintenance, 2 and 
5 years after end of 
treatment 
Abbreviations: DLCO, Diffusion capacity of the lung for carbon monoxide; FVC, Forced vital capacity; FV, Flow volume; HSCT, hematopoietic stem cell 
transplantation; SD, Standard deviation; TLC, Total lung capacity  
a Number of children in our study treated with said protocol. 90 other study protocols were used in our study, but each in five or less children.  
References: 
1 Therapy based long-term follow-up: practice statement 2nd edition, April 2005, 2005. 
https://www.uhb.nhs.uk/Downloads/pdf/CancerPbTherapyBasedLongTermFollowUp.pdf. Accessed 10 Nov 2017. 
2 COG Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancer, version 4.0–October 2013. 2013. 
http://www.survivorshipguidelines.org/. Accessed 10.11.2017. 
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Supplementary Table S2 Type of pulmonary disease diagnosis found in medical 
records, survivors can have more than one pulmonary disease 
  Survivors   
 (N=372)   
  N (%) a 
Ever had a pulmonary disease diagnosis b 72 (20) 
Noninfectious pulmonary diseases c 47 (13) 
Pulmonary infections  25 (7) 
 
  
Noninfectious pulmonary diseases:   
Asthma 19 (5) 
Diffuse parenchymal lung disease: 22 (6) 
Restrictive lung disease 20 (5) 
Interstitial lung disease 5 (1) 
Bronchiolitis obliterans 1 (<1) 
Atelectasis 3 (1) 
Chest wall deformity 2 (1) 
Emphysema 1 (<1) 
ARDS d 7 (2) 
   
Pulmonary Infections: e   
Pneumonia (viral, bacterial) 30 (8) 
Aspergillosis 5 (1) 
 
a Column percentages given  
b This includes all pulmonary disease diagnoses, which were present after the cancer diagnosis, 
regardless if the pulmonary disease was diagnosed before or after the cancer diagnosis. 
c If survivors had any of the following diseases they were categorized as pulmonary diseases: 
restrictive lung disease, asthma, interstitial lung disease, atelectasis, chest wall deformity, 
emphysema, bronchiolitis obliterans. If they had both pulmonary disease and pulmonary infection they 
were categorized into pulmonary diseases. 
d If survivors had ARDS because of a pulmonary infection they were categorized as pulmonary 
infections only; if they had ARDS because of acute treatment-related side effects and another 
pulmonary disease they were categorized as pulmonary diseases, and if they had ARDS only because 
of acute treatment related side effects, they were categorized to no pulmonary disease diagnosis. 
e Of 35 survivors with pulmonary infections 10 had additional noninfectious pulmonary diseases and 
were coded to noninfectious pulmonary diseases for further analysis. 
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Supplementary Table S3 Proportion of pulmonary function tests by Swiss pediatric 
oncology center  
  Plethysmography and/or 
spirometry 
 DLCO  
 
N=372 n (%) a (95% CI)  n (%) a (95% CI) 
    
  
  
 
Center b 
   
  
  
 
A 28 22 (79) (58–91)  22 (79) (58–91) 
B 84 49 (58) (47–69)  37 (44) (34–55) 
C 35 19 (54) (37–71)  15 (43) (27–60) 
D 17 9 (53) (28–76)  1 (6) (1–37) 
E 33 17 (52) (34–69)  11 (33) (33–91) 
F 71 35 (49) (38–61)  31 (43) (32–56) 
G 70 25 (36) (25–48)  4 (6) (2–15) 
H 34 9 (26) (14–45)  1 (3) (0–20) 
         
Abbreviations: DLCO, Diffusion capacity of the lungs for carbon monoxide  
a Row percentages are given  
b Centers are anonymized 
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Supplementary Table S4. Predictors for having a pulmonary function test in the first 5 years after pulmotoxic treatment, results from 
univariable logistic regression analysis 
    Plethysmography and/or 
spirometry 
  DLCO  
   
≥ 1 PFT 
 
≥ 1 PFT      
P b 
    
P b 
  N=372 n (%)a ORadj (95% CI)   n (%)a ORadj (95% CI) 
Overall  372 185 (50) 
   
122 (33) 
  
     
 
    
 
Sex 
    
0.410 
    
0.683 
Male 219 105 (48) 1.0  
 
70 (32) 1.0  
Female  153 80 (52) 1.2 (0.7–1.8) 
 
52 (34) 1.1 (0.7–1.7)       
 
    
 
Age at diagnosis (years) 
    
0.005 
    
0.002 
0–4 67 26 (39) 1.0  
 
13 (19) 1.0  
5–9 111 47 (42) 1.2 (0.6–2.2) 
 
30 (27) 1.5 (0.7–3.2) 
10–15 194 112 (58) 2.2 (1.2–3.8) 
 
79 (41) 2.9 (1.5–5.6)      
 
    
 
Diagnosis (ICCC-3) 
    
<0.001 
    
<0.001 
I Leukemia 46 20 (43) 1.0  
 
10 (22) 1.0  
II Lymphoma 131 100 (76) 4.2 (2.1–8.5) 
 
67 (51) 3.8 (1.7–8.2) 
IIa Hodgkin's lymphoma 120 94 (78)   
 
61 (51) 
 
 
IIb&c Non–Hodgkin's lymphoma 11 6 (55)   
 
6  (55) 
 
 
III CNS tumor 107 22 (21) 0.3 (0.2–0.7) 
 
16 (15) 0.6 (0.3–1.5) 
IV–XII all other tumors  88 43 (49) 1.2 (0.6–2.5) 
 
29 (33) 1.8 (0.8–4.1)     
  
    
 
Period of cancer diagnosis 
   
 0.482 
    
0.186 
1990–1997 130 63 (48) 1.0  
 
40 (31) 1.0  
1998–2005 144 77 (53) 1.2 (0.8–2.0) 
 
55 (38) 1.4 (0.8–2.3) 
2006–2013 98 45 (46) 0.9 (0.5–1.5) 
 
27 (28) 0.9 (0.5–1.5) 
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(Supplementary Table S4 continued) 
Pulmotoxic treatment 
    
0.959 
    
0.631 
Chest radiotherapy only 225 113 (50) 1.0  
 
72 (32) 1.0  
Pulmotoxic chemotherapy only 48 24 (50) 1.0 (0.5–1.8) 
 
14 (29) 0.9 (0.4–1.7) 
Both 99 48 (48) 0.9 (0.6–1.5) 
 
36 (36) 1.2 (0.7–2.0)      
 
    
 
Thoracic surgery  
    
0.265 
    
0.746 
No 338 165 (49) 1.0  
 
110 (33) 1.0  
Yes 34 20 (59) 1.5 (0.7–3.1) 
 
12 (35) 1.1 (0.5–2.4)      
 
   
  
Hematopoietic stem cell transplantation 
    
0.857 
   
 0.353 
No 285 141 (49) 1.0  
 
97 (34) 1.0  
Yes 87 44 (51) 1.0 (0.6–1.7) 
 
25 (29) 0.8 (0.5–1.3) 
autologous 47 24 (51)    15 (32)   
allogeneic 40 20 (50)    10 (25)   
           
Clinical study participation     0.005     0.261 
Registered as clinical study participant 217 113 (52) 1.0   69 (32) 1.0  
Treated according to clinical study protocol 124 65 (52) 1.0 (0.7–1.6)  46 (37) 1.3 (0.8–2.0) 
Treated not according to clinical study 31 7 (23) 0.3 (0.1–0.6)  7 (23) 0.6 (0.3–1.5)      
 
    
 
Ever had a pulmonary disease/infection  
    
<0.001 
    
0.077 
No 299 136 (45) 1.0  
 
92 (31) 1.0  
Noninfectious pulmonary disease  51 41 (80) 5.5 (2.6–12.5) 
 
24 (47) 2.1 (1.1–3.8) 
Pulmonary infection  22 8 (36) 0.6 (0.3–1.7) 
 
6 (27) 0.8 (0.3–2.1)      
 
   
  
Died during follow-up 
    
0.016 
    
0.250 
No 315 165 (52) 1.0  
 
107 (34) 1.0  
Yes  57 20 (35) 0.5  (0.3–0.9)   15 (26) 0.7 (0.4–1.3) 
Abbreviations: CI, confidence interval; CNS, central nervous system; DLCO, diffusion capacity of the lungs for carbon monoxide; ICCC3, international 
classification of childhood cancer, version 3; OR, odds ratio; PFT, pulmonary function test  
a Row percentages given. 
b P-values calculated from global likelihood ratio tests. 
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Supplementary Table S5 Pulmonary toxic childhood cancer treatment of CNS tumor 
survivors 
 Survivors of CNS tumors 
 N = 107 
 n (%) a 
Lung-toxic chemotherapy 63 (59) 
Nitrosoureas (CCNU/BCNU) 63 (59) 
   
Chest radiotherapy a, cumulative Gy 95 (89) 
1–19 1 (1) 
≥ 20 92 (86) 
Dose unknown 2 (2) 
   
Abbreviations: CNS, central nervous system; Gy, Gray;  
a Included fields: thoracic spine (n=94), total body irradiation (n=1) 
  
Monitoring pulmonary health in Swiss childhood cancer survivors 
Rahel Kasteler, Linda MH Kam, Annette Weiss, Nicolas Waespe, Grit Sommer, Florian Singer,  
Nicolas X von der Weid, Marc Ansari, Claudia E Kuehni, for the Swiss Pediatric Oncology Group 
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Supplementary Figure S1 Flow chart of study population 
 
a Including the following centers with pediatric oncology units: Kinderklinik Kantonsspital Aarau AG, 
Universitäts-Kinderspital Basel, Universitäts-Kinderklinik Inselspital Bern, Hospital des Enfants 
Geneve, CHUV Lausanne, Kinderklinik Kantonsspital Luzern, Ostschweizer Kinderspital St. Gallen, 
Universitäts-Kinderspital Zürich 
b Pulmotoxic treatment defined as chemotherapy with busulfan, bleomycin, lomustine or carmustine 
and/or chest radiotherapy 
 
 
Childhood cancer patients from the  
Swiss childhood cancer registry: 
- Diagnosed in a Swiss pediatric oncology center 
a
 
- Diagnosed ≤ 16 years 
- Diagnosed from 1990 to 2013 
- Survived for ≥2 years after diagnosis 
- Had no secondary tumor diagnosis 
-  
N=2989 
Medical records review 
N=419 (100%) 
Included in analysis 
n=372 (89%) 
Medical records not available, n=47 (11%) 
Not treated with pulmotoxic treatment 
b
, n=2554 
Aged <6 years at start of data collection (1 Feb 2016), n=16 
